first- and later-line use of panitumumab in metastatic colorectal cancer
Published 10 years ago • 2K plays • Length 9:00Download video MP4
Download video MP3
Similar videos
-
11:36
panitumumab, regorafenib, and ziv-aflibercept in metastatic colorectal cancer
-
5:31
later lines of therapy for metastatic colorectal cancer
-
7:31
add panitumumab or bevacizumab to improve first-line metastatic colorectal cancer therapy?
-
6:19
clinical development of cetuximab in metastatic colorectal cancer
-
13:11
treatment sequencing in metastatic colorectal cancer
-
5:54
initial systemic therapy for metastatic colorectal cancer
-
4:56
upfront bevacizumab and cetuximab compared in metastatic colorectal cancer
-
8:20
tribe trial: first-line treatment of metastatic colorectal cancer
-
5:25
second-line and salvage treatment of metastatic colorectal cancer
-
7:32
considerations when selecting an egfr inhibitor in metastatic colorectal cancer
-
4:33
first-line targeted therapies in metastatic crc
-
4:16
fire-3 study: cetuximab versus bevacizumab in metastatic colorectal cancer
-
7:28
expert report on panitumumab for first line treatment of ras wild type mcrc from asco 2022
-
9:05
determining optimal treatments in metastatic colorectal cancer
-
11:41
treating unresectable metastatic colorectal cancer
-
7:59
maintenance therapy in metastatic colorectal cancer
-
10:50
second-line treatment options in metastatic colorectal cancer
-
1:18
second line and later therapies - metastatic colorectal cancer
-
0:57
dr. peeters discusses the efficacy and safety of panitumumab versus cetuximab in colorectal cancer